Keith M. Mcgahan net worth and biography

Keith Mcgahan Biography and Net Worth

Keith McGahan has served as our Chief Legal Officer since June 2018, as Corporate Secretary since February 2018 and as Executive Vice President since June 2019. From August 2016 to June 2018, he served as Vice President, Chief Compliance Officer and Associate General Counsel. He brings to Spectrum more than 20 years of diverse experience in the healthcare, medical device and pharmaceutical industries. From 2015 through August 2016, Mr. McGahan served as Executive Director and Associate General Counsel at Avanir Pharmaceuticals. During his tenure at Avanir, Mr. McGahan served as legal advisor on all compliance and commercial related matters. From 2012 through 2015, Mr. McGahan served as Director, Healthcare Compliance at Johnson & Johnson, where he was responsible for executing the global compliance program. Prior to that, from 2003 through 2011, Mr. McGahan served as the Assistant Staff Judge Advocate to the Navy Surgeon General, Staff Judge Advocate to the Navy Medical Research Command as well as Staff Judge Advocate and Chief Compliance Officer at Naval Hospital Camp Pendleton.

Mr. McGahan is a Certified Compliance and Ethics Professional (CCEP) and holds a professional certificate in health care compliance & privacy from Seton Hall University, a Six Sigma Black Belt certification from Villanova University and is certified by UCLA’s Anderson School of Business as an accredited public company director.

Mr. McGahan holds a bachelor’s degree in Zoology from Connecticut College, a master’s degree in Business Administration from Pepperdine University, a Juris Doctorate from Seattle University School of Law and a Master of Laws in Taxation from University of San Diego School of Law.

What is Keith M. Mcgahan's net worth?

The estimated net worth of Keith M. Mcgahan is at least $178,760.56 as of March 14th, 2023. Mr. Mcgahan owns 216,522 shares of Spectrum Pharmaceuticals stock worth more than $178,761 as of March 21st. This net worth estimate does not reflect any other assets that Mr. Mcgahan may own. Learn More about Keith M. Mcgahan's net worth.

How do I contact Keith M. Mcgahan?

The corporate mailing address for Mr. Mcgahan and other Spectrum Pharmaceuticals executives is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. Spectrum Pharmaceuticals can also be reached via phone at (702) 835-6300 and via email at [email protected] Learn More on Keith M. Mcgahan's contact information.

Has Keith M. Mcgahan been buying or selling shares of Spectrum Pharmaceuticals?

In the last ninety days, Keith M. Mcgahan has sold $36,127.98 in shares of Spectrum Pharmaceuticals stock. Most recently, Keith M. Mcgahan sold 15,733 shares of the business's stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $0.82, for a transaction totalling $12,901.06. Following the completion of the sale, the insider now directly owns 216,522 shares of the company's stock, valued at $177,548.04. Learn More on Keith M. Mcgahan's trading history.

Who are Spectrum Pharmaceuticals' active insiders?

Spectrum Pharmaceuticals' insider roster includes Seth Fischer (Director), Francois Lebel (Insider), Keith Mcgahan (Insider), and Thomas Riga (COO). Learn More on Spectrum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Spectrum Pharmaceuticals?

During the last twelve months, Spectrum Pharmaceuticals insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $22,500.00. During the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 218,922 shares worth more than $139,969.16. The most recent insider tranaction occured on March, 14th when insider Keith M Mcgahan sold 15,733 shares worth more than $12,901.06. Insiders at Spectrum Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Spectrum Pharmaceuticals.

Information on this page was last updated on 3/14/2023.

Keith M. Mcgahan Insider Trading History at Spectrum Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2023Sell15,733$0.82$12,901.06216,522View SEC Filing Icon  
2/22/2023Sell11,990$0.76$9,112.40636,697View SEC Filing Icon  
1/30/2023Sell26,138$0.54$14,114.52686,887View SEC Filing Icon  
3/15/2022Sell14,658$0.70$10,260.60View SEC Filing Icon  
6/21/2021Sell3,735$4.27$15,948.45308,199View SEC Filing Icon  
5/13/2021Sell434$3.09$1,341.06312,459View SEC Filing Icon  
3/15/2021Sell14,362$3.62$51,990.44333,150View SEC Filing Icon  
2/9/2021Sell1,977$3.93$7,769.61246,998View SEC Filing Icon  
7/9/2020Sell13,881$3.36$46,640.16249,313View SEC Filing Icon  
6/24/2020Sell15,773$3.21$50,631.33262,986View SEC Filing Icon  
6/19/2020Sell3,459$3.13$10,826.67281,759View SEC Filing Icon  
5/13/2020Sell400$3.25$1,300.00285,568View SEC Filing Icon  
3/31/2020Sell1,786$2.31$4,125.66287,435View SEC Filing Icon  
2/19/2020Sell3,341$2.77$9,254.57128,708View SEC Filing Icon  
2/10/2020Sell1,667$2.73$4,550.91132,049View SEC Filing Icon  
2/7/2020Sell2,020$2.78$5,615.60133,716View SEC Filing Icon  
8/12/2019Sell294$7.77$2,284.38135,543View SEC Filing Icon  
6/19/2019Sell3,535$8.49$30,012.15135,756View SEC Filing Icon  
5/14/2019Sell458$8.82$4,039.56139,291View SEC Filing Icon  
4/11/2019Sell2,018$10.67$21,532.06139,749View SEC Filing Icon  
4/2/2019Sell1,810$10.57$19,131.70141,767View SEC Filing Icon  
2/7/2019Sell2,496$11.03$27,530.88103,577View SEC Filing Icon  
8/8/2018Sell437$20.96$9,159.52105,993View SEC Filing Icon  
See Full Table

Keith M. Mcgahan Buying and Selling Activity at Spectrum Pharmaceuticals

This chart shows Keith M Mcgahan's buying and selling at Spectrum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spectrum Pharmaceuticals Company Overview

Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More

Today's Range

Now: $0.83
Low: $0.78
High: $0.83

50 Day Range

MA: $0.76
Low: $0.50
High: $1.07

2 Week Range

Now: $0.83
Low: $0.32
High: $1.57


1,178,191 shs

Average Volume

1,876,693 shs

Market Capitalization

$167.77 million

P/E Ratio


Dividend Yield